Laquinimod Approval Status
- FDA approved: No
- Generic name: laquinimod
- Company: Teva Pharmaceutical Industries Ltd. and Active Biotech
- Treatment for: Multiple Sclerosis, Huntington's Disease
Laquinimod is an oral, CNS-active immunomodulator in development for the treatment of relapsing-remitting multiple sclerosis (RRMS), primary-progressive multiple sclerosis (PPMS) and Huntington disease.
Development Status and FDA Approval Process for laquinimod
|Jan 4, 2016||Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials|
|Jun 25, 2015||Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.